Dyne Therapeutics director Dirk Kersten disposes of 261,460 common shares worth $6.67 millionPUBT·1 hour agoDYN-3.09%
Dyne Therapeutics: Buy Rating Reiterated as FORCE Platform Expands; $47 Price Target MaintainedTip Ranks·9 hours agoDYN-3.09%
Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD)Unusual Whales·1 day ago, 06:34 AMDYN-3.09%
Biotech Stocks At 52-Week Highs - LH Rises With Genetic Testing Launch, DYN, SNDA, SLN, AMLX,rttnews·1 day ago, 03:30 AMSLN0.00%LH-2.25%
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | DYN Stock NewsStockTitan·Jul 24 at 07:05 AMDYN-3.09%
Dyne Therapeutics closes upsized public offering of 21,045,000 shares at $20.5 eachPUBT·Jul 23 at 03:29 PMDYN-3.09%EVR-10.51%
Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional SharesUnusual Whales·Jul 23 at 03:08 PMDYN-3.09%
Dyne Therapeutics Upsized Equity Offering Strengthens Cash RunwayTip Ranks·Jul 22 at 04:51 PMDYN-3.09%
Dyne Therapeutics slides 3% in regular trading on earnings pressureUS Stock Market Update·Jul 22 at 01:50 PMDYN-3.09%
Dyne Therapeutics falls 7% during regular trading on earnings pressureUS Stock Market Update·Jul 22 at 11:11 AMDYN-3.09%
Biggest stock movers Wednesday: SMCI, DYN, GEV, T, and moreMSN·Jul 22 at 09:05 AMGEV-4.57%GOOGL+0.90%
